Montelukast Cristers (Montelukast)

Montelukast selectively blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotriene D4 from binding. This inhibition reduces bronchoconstriction, mucus production, vascular permeability and inflammatory cell recruitment, thereby improving airway patency and decreasing allergic inflammation.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s age, diagnosis and overall treatment plan. Montelukast is typically prescribed as a once‑daily oral tablet, but the exact regimen should follow the prescriber’s instructions.

Safety data for montelukast in pregnancy are limited, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies the potential risk to the fetus. Caution is also advised during breastfeeding, as the drug is excreted in milk; a healthcare professional should evaluate the risk‑benefit ratio.

To place an enquiry, visit the product page on gnhindia.com, enter the required quantity and submit the request. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. While inhaled steroids target a broader range of inflammatory pathways, montelukast specifically blocks leukotriene‑mediated effects, making it useful as add‑on therapy or for patients who prefer oral medication. It is generally less potent than high‑dose inhaled steroids but may have a more favorable side‑effect profile for some individuals.

Montelukast Cristers should be stored at room temperature, below 25 °C. Keep the tablets in the original container, protect them from moisture, direct sunlight and excessive heat to maintain product stability throughout its shelf life.

Montelukast Cristers is taken orally as a tablet. The tablet should be swallowed whole with water, preferably at the same time each day, and can be taken with or without food according to the prescriber’s guidance.

Serious adverse reactions, although rare, include angioedema, severe allergic responses such as anaphylaxis, and neuropsychiatric events like depression, suicidal thoughts or behavior. Patients should be instructed to seek immediate medical attention if they experience swelling of the face or throat, rash, or any sudden changes in mood.

Montelukast is contraindicated in individuals with known hypersensitivity to montelukast or any of the tablet’s excipients. Caution is also advised for patients with severe hepatic impairment, and it should be avoided in patients who have experienced serious neuropsychiatric reactions while on the drug.